JP6888026B2 - 概日リズム睡眠障害群を治療する方法 - Google Patents

概日リズム睡眠障害群を治療する方法 Download PDF

Info

Publication number
JP6888026B2
JP6888026B2 JP2018558728A JP2018558728A JP6888026B2 JP 6888026 B2 JP6888026 B2 JP 6888026B2 JP 2018558728 A JP2018558728 A JP 2018558728A JP 2018558728 A JP2018558728 A JP 2018558728A JP 6888026 B2 JP6888026 B2 JP 6888026B2
Authority
JP
Japan
Prior art keywords
sleep
pharmaceutical composition
subject
formula
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018558728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019518732A5 (cg-RX-API-DMAC7.html
JP2019518732A (ja
Inventor
カーステン， ティー． ボイクマン，
カーステン， ティー． ボイクマン，
マーガレット モリーン，
マーガレット モリーン，
アンドリュー サットリン，
アンドリュー サットリン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2019518732A publication Critical patent/JP2019518732A/ja
Publication of JP2019518732A5 publication Critical patent/JP2019518732A5/ja
Priority to JP2021084719A priority Critical patent/JP7150096B2/ja
Application granted granted Critical
Publication of JP6888026B2 publication Critical patent/JP6888026B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018558728A 2016-05-12 2017-05-11 概日リズム睡眠障害群を治療する方法 Active JP6888026B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021084719A JP7150096B2 (ja) 2016-05-12 2021-05-19 概日リズム睡眠障害群を治療する方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662335599P 2016-05-12 2016-05-12
US201662335611P 2016-05-12 2016-05-12
US62/335,599 2016-05-12
US62/335,611 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US62/413,976 2016-10-27
US201662414599P 2016-10-28 2016-10-28
US201662414606P 2016-10-28 2016-10-28
US62/414,599 2016-10-28
US62/414,606 2016-10-28
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021084719A Division JP7150096B2 (ja) 2016-05-12 2021-05-19 概日リズム睡眠障害群を治療する方法

Publications (3)

Publication Number Publication Date
JP2019518732A JP2019518732A (ja) 2019-07-04
JP2019518732A5 JP2019518732A5 (cg-RX-API-DMAC7.html) 2020-06-18
JP6888026B2 true JP6888026B2 (ja) 2021-06-16

Family

ID=58745465

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018558728A Active JP6888026B2 (ja) 2016-05-12 2017-05-11 概日リズム睡眠障害群を治療する方法
JP2021084719A Active JP7150096B2 (ja) 2016-05-12 2021-05-19 概日リズム睡眠障害群を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021084719A Active JP7150096B2 (ja) 2016-05-12 2021-05-19 概日リズム睡眠障害群を治療する方法

Country Status (16)

Country Link
US (2) US11096941B2 (cg-RX-API-DMAC7.html)
EP (2) EP3454859B1 (cg-RX-API-DMAC7.html)
JP (2) JP6888026B2 (cg-RX-API-DMAC7.html)
KR (2) KR102511855B1 (cg-RX-API-DMAC7.html)
CN (1) CN109640998A (cg-RX-API-DMAC7.html)
AU (3) AU2017264871B2 (cg-RX-API-DMAC7.html)
CA (1) CA3022068A1 (cg-RX-API-DMAC7.html)
ES (1) ES2904625T3 (cg-RX-API-DMAC7.html)
IL (2) IL291791B2 (cg-RX-API-DMAC7.html)
MX (1) MX379318B (cg-RX-API-DMAC7.html)
MY (1) MY199382A (cg-RX-API-DMAC7.html)
RU (1) RU2763493C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201809527UA (cg-RX-API-DMAC7.html)
TW (1) TWI795359B (cg-RX-API-DMAC7.html)
WO (1) WO2017197160A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201807903B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021120410A (ja) * 2016-05-12 2021-08-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 概日リズム睡眠障害群を治療する方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
MX2021016090A (es) * 2019-06-26 2022-02-03 Eisai R&D Man Co Ltd Lemborexant para el tratamiento de problemas del sueño.
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
CA3151634A1 (en) * 2019-09-13 2021-03-18 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating insomnia
US20240010629A1 (en) * 2019-12-11 2024-01-11 Teva Czech Industries S.R.O Solid state form of lemborexant
MX2022008260A (es) * 2020-01-16 2022-08-04 Eisai R&D Man Co Ltd Sustancia farmacologica de lemborexant y composicion medicinal que la comprende.
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
JP2024527024A (ja) * 2021-07-26 2024-07-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性疾患に伴う不規則睡眠・覚醒リズム障害及び概日リズム睡眠障害を治療する方法における使用のためのレンボレキサント
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用
KR20250070087A (ko) * 2022-09-23 2025-05-20 에자이 알앤드디 매니지먼트 가부시키가이샤 신경변성 질병과 관련된 신경변성의 감소 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06009377A (es) * 2004-02-20 2007-03-07 Lifescape Biosciences Inc Composiciones y metodos para regulacion del sueno.
WO2008026149A1 (en) * 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
MX2013003218A (es) 2010-09-22 2013-06-28 Eisai R&D Man Co Ltd Compuestos de ciclopropano.
CA2863413A1 (en) * 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
CN107810006B (zh) * 2014-10-23 2021-03-30 卫材R&D管理有限公司 用于治疗失眠的组合物
SG11201809527UA (en) * 2016-05-12 2018-11-29 Eisai R&D Man Co Ltd Methods of treating circadian rhythm sleep disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021120410A (ja) * 2016-05-12 2021-08-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 概日リズム睡眠障害群を治療する方法
JP7150096B2 (ja) 2016-05-12 2022-10-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 概日リズム睡眠障害群を治療する方法

Also Published As

Publication number Publication date
EP3454859A1 (en) 2019-03-20
RU2763493C2 (ru) 2021-12-29
IL291791B2 (en) 2025-09-01
EP3454859B1 (en) 2021-12-01
IL291791B1 (en) 2025-05-01
US20200179382A1 (en) 2020-06-11
TWI795359B (zh) 2023-03-11
IL262803A (en) 2018-12-31
SG11201809527UA (en) 2018-11-29
IL291791A (en) 2022-06-01
AU2023203418A1 (en) 2023-06-29
MX2018013663A (es) 2019-07-18
ZA201807903B (en) 2021-04-28
ES2904625T3 (es) 2022-04-05
AU2017264871B2 (en) 2023-03-16
MY199382A (en) 2023-10-25
JP2021120410A (ja) 2021-08-19
WO2017197160A1 (en) 2017-11-16
IL262803B (en) 2022-05-01
JP2019518732A (ja) 2019-07-04
AU2017264871A1 (en) 2018-11-15
CN109640998A (zh) 2019-04-16
KR20190013820A (ko) 2019-02-11
KR20230043227A (ko) 2023-03-30
TW201740952A (zh) 2017-12-01
RU2018143809A3 (cg-RX-API-DMAC7.html) 2020-09-17
KR102511855B1 (ko) 2023-03-20
CA3022068A1 (en) 2017-11-16
NZ748555A (en) 2025-06-27
RU2018143809A (ru) 2020-06-15
AU2025205336A1 (en) 2025-07-31
US20210353625A1 (en) 2021-11-18
MX379318B (es) 2025-03-10
US11096941B2 (en) 2021-08-24
JP7150096B2 (ja) 2022-10-07
BR112018073037A2 (pt) 2019-02-26
EP4056180A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
JP6888026B2 (ja) 概日リズム睡眠障害群を治療する方法
Salín-Pascual et al. Caffeine challenge in insomniac patients after total sleep deprivation
JP2003522147A (ja) 睡眠障害の治療のためのミルタザピンの使用
US20250064802A1 (en) Methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
US20220305012A1 (en) Lemborexant for treating sleep issues
HK40007283A (en) Methods of treating circadian rhythm sleep disorders
NZ787958A (en) Methods of treating circadian rhythm sleep disorders
BR112018073037B1 (pt) Uso de um composto
BR122024003210A2 (pt) Uso de um composto
EP3989976A1 (en) Lemborexant for treating sleep issues
WO2020263331A1 (en) Lemborexant for treating sleep issues
JP2025116005A (ja) 睡眠問題の治療のためのレンボレキサント
Lee et al. Clinical comparison between barbiturate and propofol coma therapy in the patients with severe traumatic brain injury
JP2025121388A (ja) 認知機能を改善するための薬物を調製するための組成物の使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200507

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210519

R150 Certificate of patent or registration of utility model

Ref document number: 6888026

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250